Comparing two drugs and their combination for treating ulcerative colitis

Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis (COMBO-UC)

This study is testing if using a combination of two drugs, infliximab and ustekinumab, can help adults with moderate to severe ulcerative colitis feel better compared to using each drug alone.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 172 (estimated)
• Ages: 18 Years to 64 Years
• Sex: All
• Sponsor: Medical University of Lodz (Academic / other)
• Drugs / interventions: prednisone, infliximab, ustekinumab
• Locations: 1 site (Lodz)
• Trial ID: NCT06453317 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to determine whether a combination therapy of infliximab and ustekinumab is more effective than using these medications individually in adults with moderately to severely active ulcerative colitis. The study will assess improvements in symptoms, intestinal healing, and quality of life, as well as monitor any medical issues arising from the combination therapy. Participants will receive treatment according to a specified schedule and will be evaluated at designated clinic visits.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 to 65 who have been diagnosed with ulcerative colitis for at least three months.

Not a fit: Patients who are outside the age range of 18 to 65 or who have not been diagnosed with ulcerative colitis may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a more effective treatment option for patients suffering from ulcerative colitis.

How similar studies have performed: While the combination of these therapies is being explored, similar studies have shown promise in treating inflammatory bowel diseases, making this approach potentially beneficial.

Eligibility criteria

Inclusion Criteria:

1. Obtaining informed, written consent for the patient's participation in the in the study and for all planned procedures.
2. Age ≥ 18 years and ≤65 at the time of screening.
3. In the case of women of reproductive potential, agreement to not donate oocytes for the entire period of participation in the in the study and 6 months after receiving the last dose of the drug.
4. For women of reproductive potential, agreement to use effective contraception (Table 4) during the entire period, during which the patient participates in the study and for a period counted from the last dose of 15 weeks if using UST (patients in arms B and C) or 6 months if using IFX (patients in arm A).
5. Negative serum or urine pregnancy test in women of childbearing age.
6. Diagnosis of UC a minimum of. 3 months prior to screening documented by:

   (a) medical source documentation of the patient with the result of an endoscopic examination that diagnosed features typical of UC.

   (b) a histopathological examination result consistent with UC. In the absence of a histopathological result, it is possible to take sections during the endoscopic examination for histopathological evaluation at the time of eligibility for the study with subsequent sending of the material to the local pathomorphology laboratory to confirm the diagnosis of UC before randomization.
7. UC with moderate or severe activity defined as a Mayo scale score (Appendix 2) of 7 to 12 including the following sub-item values (each sub-item 0-3 points depending on the severity of the lesions):

   \- Frequency of bowel movements
   * Bowel bleeding
   * Endoscopic image of the colonic mucosa
   * General medical evaluation and:
   * with inadequate response to standard treatment, including corticosteroids and 6-mercaptopurine or azathioprine, or.
   * intolerant of treatment with corticosteroids and 6-mercaptopurine or azathioprine, or
   * having contraindications to treatment with corticosteroids and 6-mercaptopurine or azathioprine, or
   * with loss of response to standard treatment, including to treatment with corticosteroids and 6-mercaptopurine or azathioprine, including patients:
   * Steroid-resistant - in whom there is no clinical improvement despite the use of a daily steroid up to 0.75 mg/kg prednisolone for 4 weeks;
   * Steroid-dependent - in whom failure to reduce the steroid dose below 10 mg/day, converted to prednisolone, within 3 months of starting steroid therapy or relapse of complaints within 3 months of steroid withdrawal.
   * Refractory patients/about inadequate response to immunosuppressive treatment, defined as lack of remission or recurrence of complaints despite immunosuppressive treatment for at least 3 months at appropriate doses (azathioprine 2-2.5 mg/kg/day or 6-mercaptopurine 1-1.5 mg/kg/day).
8. Patients taking 5-ASA derivatives, corticosteroids, immunosuppressants may be included in the study if they are taking a fixed and specified dose of the above drugs 14 days before the day of randomization.

Exclusion Criteria:

1. Previous use of the study drug IFX or UST.
2. Hypersensitivity to the active substance or excipients.
3. Moderate or severe myocardial insufficiency (NYHA III or IV).
4. Unstable coronary artery disease.
5. History of serious cerebrovascular disease (stroke, intracranial hemorrhage, transient cerebral ischemia) within the last 24 weeks prior to screening.
6. Chronic respiratory failure.
7. Severe chronic renal failure.
8. Severe chronic liver failure.
9. Demyelinating syndrome or symptoms resembling the syndrome.
10. Alcoholic disease, post-alcoholic liver damage.
11. Diagnosis of malignant neoplasms, including within 5 years preceding the time of eligibility for the program (except for carcinoma in situ of the cervix, and non-melanoma skin cancers).

12 Complications requiring other management (e.g., surgery). 13. Current or recent (defined as an incident within 12 weeks prior to randomization) documented episode of fulminant colitis, or intra-abdominal abscess, or acute colonic distension, or bowel perforation.

14\. Status after extensive colorectal resection, subtotal or total colectomy with or without colostomy, or J-pouch reservoir.

15\. Indication of surgical intervention due to underlying disease or when there is a suspicion of need for such intervention during the course of the study.

16\. History of current or previously documented unclassified colitis or ischemic colitis.

17\. History of colonic diverticulitis within the last 60 days prior to the randomization visit.

18\. Current adenomatous polyps of the colon, small- or large-grade dysplasia in colon specimens, or previously diagnosed foci of large-grade dysplasia that have not been treated.

19\. Enteral nutrition or total parenteral nutrition. 20. Pregnancy or breastfeeding. 21. Taking medications on the prohibited drugs list (Section 7.4.6). 22. daily dose of prednisone\> 40 mg (or equivalent other corticosteroid) or budesonide MMX \> 9 mg.

23\. Status after bone marrow transplantation. 24. Condition after apheresis 12 months prior to the randomization visit. 25. Period after administration of allowed biologic drugs shorter than the drug's washout period from the body (Section 7.2).

26\. Period after intestinal microbiota transplantation less than 8 weeks before signing informed consent to participate in the study.

27\. Active or latent form of tuberculosis. 28. HIV infection. 29. Treatment period for active lesions of chronic infections (including pneumocystodosis, CMV, HPV, HSV infection, atypical mycobacteriosis, invasive bacterial or fungal infections).

30 History of HSV, HPV, influenza virus, SARS-CoV2 infection within 12 weeks prior to randomization or history of disseminated or complicated HSV infection.

31\. History of congenital or acquired immunodeficiency. 32. receipt of live vaccine within 30 days prior to randomization. 33. infection with HBV or HCV. 34. Clinically significant changes on chest X-ray or ECG. 35 Clinically significant changes observed in laboratory test results:

1. ALT activity \>3x the upper limit of normal (GGN)
2. AST activity \>3x GGN
3. Total bilirubin level \>2x GGN (exception is Gilbert syndrome when other causes of isolated hyperbilirubinemia are excluded).
4. ALP or GGTP activity \>3x GGN
5. Creatinine level \>2x GGN or impaired renal function (eGFR) \<45mL/min calculated by MDRD formula.
6. Hemoglobin level \<9g/dL
7. Absolute leukocyte count \<3000/mm3
8. Absolute lymphocyte count \<750/mm3
9. Neutrophil level \<1000/mm3
10. Platelet level \<100000/mm3. 36. Positive stool culture for bacteria/fungus (if clinically relevant in the opinion of the investigator).

    37.Positive stool culture for Clostridioides difficile. 38. Use of treatment not permitted under this protocol.

Where this trial is running

Lodz

• Oddział Kliniczny Gastroenterologii Ogólnej i Onkologicznej USK nr 1 im. N. Barlickiego w Łodzi — Lodz, Poland (Recruiting)

Study contacts

• Principal investigator: Renata Talar-Wojnarowska, Prof. — Medical University of Lodz
• Study coordinator: Renata Talar-Wojnarowska, Prof.

Conditions Ulcerative Colitis; Inflammatory Bowel Diseases; dual biological therapy; infliximab; ustekinumab